Aim: Potassium 2-(1-hydroxypentyl)-benzoate (dl-PHPB) is a new drug candidate for ischemic stroke. The aim of this study was to investigate the effects of dl-PHPB on memory deficits and long-term potentiation (LTP) impairment in animal models of Alzheimer's disease. Methods: The expression of NMDA receptor subunits GluN1 and GluN2B in the hippocampus and cortex of APP/PS1 transgenic mice were detected using Western blot analysis. Memory deficits of the mice were evaluated with the passive avoidance test. LTP impairment was studied in the dentate region of Aβ 1-42 -injected rats and APP/PS1 transgenic mice. Results: APP/PS1 transgenic mice showed significantly lower levels of GluN1 and p-GluN2B in hippocampus, and chronic administration of dl-PHPB (100 mg·kg -1 ·d -1 , po) reversed the downregulation of p-GluN2B, but did not change GluN1 level in the hippocampus. Furthermore, chronic administration of dl-PHPB reversed the memory deficits in APP/PS1 transgenic mice. In the dentate region of normal rats, injection of dl-PHPB (100 μmol/L, icv) did not change the basal synaptic transmission, but significantly enhanced the high-frequency stimulation (HFS)-induced LTP, which was completely prevented by pre-injection of APV (150 μmol/L, icv). Chronic administration of dl-PHPB (100 mg·kg -1 ·d -1
Introduction
Potassium 2-(1-hydroxypentyl)-benzoate (dl-PHPB) is a novel compound synthesized by the Institute of Materia Medica, Chinese Academy of Medical Sciences. Previous studies showed that dl-PHPB ameliorates the effects of ischemic stroke via reducing the infarct volume and improving regional cerebral blood flow in a rat model of transient middle cerebral artery occlusion (tMCAO) [1] . In 2009, dl-PHPB was approved to undergo phase I clinical trial by the State Food and Drug Administration as a new drug candidate for ischemic stroke. Recently, the phase I clinical trial was completed, and phase II and phase III clinical trials were approved. In addition to the protective effects of dl-PHPB in cerebral ischemia, our preliminary studies showed that dl-PHPB ameliorated the learning and memory deficits in rats that were cerebrally hypoperfused and in rats that were icv infused with β-amyloid (Aβ) [2] . These results suggest that dl-PHPB may have therapeutic effects against dementia and Alzheimer's disease (AD). However, the ameliorative effects of dl-PHPB in AD animal models in vivo and the possible mechanisms underlying its effects on synaptic plasticity remain to be studied.
Synaptic plasticity is one of the most important properties of the mammalian brain; it refers to the activity-dependent modification of the strength or efficacy of synaptic transmission at preexisting synapses. For more than a century, synaptic plasticity has been proposed to play a central role in the capacity of the brain to incorporate transient experiences into persistent memory traces [3] . Long-term potentiation (LTP) is a form www.nature.com/aps Li PP et al Acta Pharmacologica Sinica npg of synaptic plasticity that has been widely used as a cellular model of learning and memory mechanisms. Various physiological and pathological processes are associated with AD. These processes can influence LTP induction and maintenance, and they include Aβ-induced neuronal toxicity, acetylcholine system dysfunction and changes in NMDA receptor expression. A number of groups have reported that Aβ administration can negatively affect synaptic plasticity. For instance, Aβ peptides have been shown to inhibit LTP in the CA1 region [4, 5] and dentate gyrus (DG) both in vivo and in vitro [6] [7] [8] [9] . Transgenic models of AD such as APP and APP/PS1 mice display early deficits in synaptic plasticity and memory, even before developing typical AD pathology and behavioral deficits [10] [11] [12] [13] . Moreover, drugs that have been reported to improve memory impairment also show ameliorative effects on LTP [14] [15] [16] . In the present study, to investigate the actions of dl-PHPB on AD models in vivo and the possible electrophysiological mechanisms of dl-PHPB, we investigated the effects of dl-PHPB on memory capability and synaptic plasticity (LTP) under physiological and AD-associated pathological conditions, including in rats that had been icv injected with Aβ 1-42 and in APP/PS1 transgenic (Tg) mice. In addition, we examined the effects of dl-PHPB on LTP mediated by NMDA and AMPA/kainate receptors, which are the major excitatory amino-acid receptors, in APP/PS1 mice.
Materials and methods

Animals and treatment
Male Wistar rats (3 months old, 220-250 g) used in LTP recording were obtained from the Experimental Animal Center of the Chinese Academy of Medical Sciences, Beijing. APP/PS1 double-Tg mice were purchased from the Jackson Laboratory (strain name: B6C3-Tg (AβPPswe, PSEN1dE9) 85Dbo/J, stock number: 004462). These mice express a chimeric mouse/ human AβPP containing the K595N/M596L Swedish mutations and a mutant human PS1 carrying the exon-9-deleted variant under the control of mouse prion promoter elements, directing transgenic expression predominantly to CNS neurons [17] . The 2 transgenes cosegregate in these mice. All animals were housed in a temperature-and humidity-controlled room (temperature: 22±1 °C, humidity: 60%) and had access to standard rodent chow and fresh tap water ad libitum. They were kept on a 12 h light/dark cycle and adapted to these conditions for at least 7 d before experiments. All experiments were performed in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of our institute.
dl-PHPB was synthesized (purity>99%) by the Department of Medical Synthetic Chemistry, Institute of Materia Medica, Chinese Academy of Medical Sciences. Male APP/PS1 Tg mice and wild-type (WT) littermates were randomly divided into 4 groups: treated APP/PS1 mice, untreated APP/PS1 mice, treated WT mice, and untreated WT mice. Treated groups received dl-PHPB dissolved in normal saline solution by oral gavage for 5 d per week at a dose of 100 mg/kg body weight.
Untreated groups received normal saline solution alone as a vehicle control. Treatment was started when the mice were 13 months old and lasted for 4 weeks. The body weight of each mouse was recorded every 2 weeks. After the treatment, half of the mice in each group were used for behavioral testing, and the other mice were used for LTP recording. The mice were sacrificed after behavioral testing was completed. Their brains were removed, snap-frozen in liquid nitrogen and stored at -80 ºC until analysis.
Step-down passive avoidance test The step-down passive avoidance test was conducted in an apparatus (STT-2, Institute of Materia Medica, Chinese Academy of Medical Sciences) that consisted of a cylindrical rubber platform (4.5 cm in diameter and 4.5 cm in height) fixed at the left end of an acrylic box (33 cm×11 cm×11 cm) with an electrifiable metallic grid floor connected to an electric shock generator. When a mouse was placed on the grid floor of the box, it would suffer an inescapable intermittent electric shock (1 s, 36 V), and the platform provided a shelter for the mouse. The experiments were conducted between 8:00 and 16:00. Before the beginning of the acquisition trial, the mouse was placed in the box to adapt for 3 min without electric shock. Then, the mouse was placed on the platform. The acquisition trial began when the animal stepped down from the platform and placed all 4 paws on the grid floor. On receiving the electric shock, the mouse escaped to the platform. The duration of the training test was 5 min, and the shock was maintained for this period. The error numbers (the times the mouse stepped down from the platform and received a shock) were recorded during this period. The retention test was carried out 24 h after the acquisition trial in a manner similar to the training except that no electric shock was delivered to the grid floor.
Step-down latency (duration of staying on the platform) and error numbers were recorded to assess the level of retention of passive avoidance. If the mouse did not step down to the grid floor within 3 min, a ceiling score of 180 s was assigned.
Electrophysiological recording
In vivo preparation Male Wistar rats (220-250 g) and mice were anesthetized with urethane (1.2 g/kg), placed in a stereotaxic frame and assessed for LTP. Small holes were drilled in the skull at the positions of the stimulating electrodes and recording electrode. For Wistar rats, the stimulating electrode (bipolar stainless steel) was positioned in the perforant path (7.5 mm posterior to bregma, 4.2 mm lateral to midline and 3.0 mm vertical to dura). The recording electrode (mono-polar stainless steel) was placed in the DG region (3.8 mm posterior to bregma, 2.5 mm lateral to midline and 3.5 mm vertical to dura). A separate hole was drilled to introduce a guide cannula for icv injection of drug or vehicle. The cannula was positioned above the lateral ventricle in the opposite hemisphere from that of the recording or stimulating electrodes (0.8 mm posterior, 1.2 mm lateral to bregma and 3.5 mm from the cranial theca). For mice, the stimulating electrode (bipolar stainless steel) was www.chinaphar.com Li PP et al Acta Pharmacologica Sinica npg positioned in the perforant path (3.8 mm posterior to bregma, 3.0 mm lateral to midline and 1.5 mm vertical to dura). The recording electrode (mono-polar stainless steel) was placed in the DG region (2.0 mm posterior to bregma, 1.4 mm lateral to midline and 1.5 mm vertical to dura).
Test stimuli were delivered to the perforant path every 30 s (0.033 Hz, 100 μs duration). The depth of the recording and stimulating electrodes was gently adjusted to maximize the amplitude of the extracellular population spike (PS). Baseline population spikes were recorded at 40% of maximal response. The amplitude of PS was used to measure synaptic efficacy.
Induction of LTP in DG in vivo
Baseline PS amplitude was monitored and recorded for at least 30 min prior to the application of a series of high-frequency stimulations (HFS: 10 trains of 10 stimuli at 100 Hz, intertrain interval of 200 ms). This protocol produced a robust LTP response in our previous study (data not shown). Population spikes evoked by low-frequency stimulation (0.033 Hz) were then recorded for a further 60 min after HFS application.
Data collection and data analysis
Extracellular field potentials were amplified, filtered at 5 kHz, digitized and recorded using a TDT RA16PA amplifier and a TDT RX7-5 processor (Tucker-Davis Technologies, Alachua, FL, USA) and observed with OpenEx software (Tucker-Davis Technologies, Alachua, FL, USA). PS amplitudes were collected every 30 s, and the averaged responses of 10 stimuli were measured every 5 min throughout the experiment. The baseline PS amplitude was monitored and recorded for a 30-min period before application of HFS. This value was used as 100% of the PS amplitude baseline, and all subsequent recorded values were normalized to this baseline value. Successful induction of LTP was defined as a change in the amplitude of the PS exceeding 20%. Error bars on the graphs represent the SEM. Control experiments in which vehicle was icv applied were interleafed between test experiments.
Western blotting analysis APP/PS1 mice were decapitated, and hippocampal samples from the mice were homogenized thoroughly and then lysed in a RIPA lysis buffer (50 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1% NP40, 0.5% sodium deoxycholate and 0.1% SDS). Protein concentrations were measured with a BCA kit (Pierce Labs, Rockford, IL, USA). Protein samples (40 μg per lane) were separated on polyacrylamide gels, transferred to PVDF membranes, blocked with 5% milk solution (nonfat dry milk in TBST) for 2 h, and subsequently incubated overnight with primary antibodies diluted in blocking solution. The following antibodies were used for Western blotting: monoclonal rabbit anti-GluN1 antibody (1:500, Cell Signaling Technology, Beverly, MA, USA), monoclonal rabbit anti-GluN2B antibody (1:500, Cell Signaling Technology), monoclonal rabbit antiphosphorylated GluN2B (p-GluN2B) antibody (1:500, Cell Signaling Technology) and monoclonal mouse anti-β-actin antibody (1:10000, Sigma, St Louis, MO, USA). After being washed with TBST for 5 times, the membrane was incubated with secondary antibodies (horseradish peroxidase-conjugated anti-mouse, anti-rabbit or anti-goat IgG) at room temperature for 1 h. The signals were detected using an enhanced chemiluminescence kit, scanned using an LAS4000 Fujifilm imaging system (Fujifilm, Tokyo, Japan) and analyzed by densitometric evaluation using Quantity-One software (Bio-Rad, Hercules, CA, USA). The values were normalized to β-actin intensity levels.
Aβ oligomer preparation and application Aβ oligomers were prepared according to previously published protocols [18] . Synthetic Aβ 1-42 purchased from Sigma was dissolved in hexafluor-2-propanol (HFIP), aliquoted and kept at -80 °C after evaporation of HFIP. Aβ oligomers were freshly prepared by dissolving the above peptide film in dimethyl sulphoxide and diluting it into cold F12 medium without phenol red to yield a 100 μmol/L stock. This preparation was incubated at 4 °C for 24 h and centrifuged at 14 000×g for 10 min at 4 °C, and the supernatant was further used for electrophysiological experiments.
According to previous reports [19, 20] , the volume of rat cerebrospinal fluid (CSF) varies between 300 and 580 μL, depending on the size of the animal. We estimate that for a rat of 220-250 g, the volume of CSF is approximately 500 μL. Calculation of the concentration of Aβ 1-42 was based on this volume.
Statistical analysis
GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA) was used to analyze the data. All data are expressed as means±SEM. Statistical significance was evaluated via Student's t-test or one-way analysis of variance followed by appropriate post tests using SPSS software (SPSS Inc, Chicago, IL, USA). A value of P<0.05 was considered statistically significant.
Results
dl-PHPB ameliorated memory deficits in APP/PS1 Tg mice
The effects of dl-PHPB on the impairment of behavioral performance in aged AD model Tg mice were evaluated. APP/ PS1 Tg mice, which express both mutant human APP and PS1, were chosen for the following experiments. After oral treatment with dl-PHPB for 1 month, the behavior of the APP/PS1 mice at the age of 14 months was tested with the step-down passive avoidance test.
Escape latency was recorded in the retention test session, representing the time spent by animals before stepping down from a platform onto an electrified grid floor. APP/PS1 Tg control mice spent significantly less time on the platform than the WT control group (Tg control: 64.5±16.7 s, n=15; WT control: 115.5±32.0 s, n=13; P<0.05 vs WT control group; Figure  1A) , indicating obvious memory deficits in Tg mice. However, dl-PHPB-treated APP/PS1 Tg mice (100 mg/kg for 1 month, po) spent significantly more time (Tg dl-PHPB: 157.3±43.6 s, n=15) on the platform compared with untreated Tg mice (P<0.01 vs Tg control group, Figure 1A ). Figure 1B ). Therefore, these results suggest that oral treatment with dl-PHPB ameliorated the impairment of behavioral performance in aged AD Tg mice.
Effects of dl-PHPB on basal synaptic transmission and LTP in the DG region of normal rats The effect of dl-PHPB on basal excitatory synaptic transmission in the hippocampal DG region of anesthetized rats was evaluated. Figure 2A and 2B), suggesting that dl-PHPB did not affect basal synaptic transmission. To assess whether dl-PHPB affected synaptic plasticity in normal rats, the effect of dl-PHPB on HFS-induced LTP in the hippocampal DG region was examined. As shown in Figure 2C , pre-injection with dl-PHPB (1 mmol/L in 5 μL, Figure 1 . dl-PHPB reversed the Aβ 1-42 induced LTP impairment in hippocampus in vivo A number of groups have reported that acute treatment with Aβ 1-42 inhibits LTP induction in the DG region both in vitro and in vivo [15] . As we previously reported, dl-PHPB ameliorates behavioral deficits induced by icv infusion of Aβ; thus, it is important to investigate the effects of dl-PHPB on Aβ-induced LTP impairment in vivo to evaluate the possibility of applying dl-PHPB in AD therapy.
In the current study, based on a previous report [21] , Aβ Figure 3 ). These results suggested that oral treatment with dl-PHPB prevents the LTP impairment caused by Aβ 1-42 injection.
dl-PHPB reversed the LTP impairment in APP/PS1 Tg mice in vivo To investigate whether the dl-PHPB-mediated improvement in memory deficits correlated with synaptic plasticity in a Tg AD model, the effect of long-term treatment with dl-PHPB on HFSinduced LTP in the hippocampal DG region was examined in APP/PS1 mice in vivo.
Strong LTP was induced in the DG region in WT control mice aged 14 months, whereas only weak LTP was observed in APP/PS1 Tg mice. Statistical analysis showed a significant difference between these 2 groups (Tg control: 167.9%±13.5%, n=5; WT control: 265.2%±17.7%, n=5; P<0.01; Figure 4 ). Treating APP/PS1 Tg mice with dl-PHPB at 100 mg/kg orally for 1 month enhanced LTP (Tg dl-PHPB: 236.5%±19.0%, n=5) 129.6%±4.8%, n=5; dl-PHPB group: 247.8%±13.5%, n=9; P<0.01; Figure 5A ). To determine whether the dl-PHPB-induced LTP improvement was also mediated by other receptors, the effects of DNQX, an antagonist of AMPA and Kainate receptors, on dl-PHPB-induced LTP improvement were observed. The results indicated that the application of DNQX (100 μmol/L in CSF, icv) 40 min before HFS suppressed LTP ( Figure 5B ). dl-PHPB-induced LTP improvement was also attenuated when DNQX was injected 10 min before application of dl-PHPB (1 mmol/L in 5 μL, approximately 10 μmol/L in CSF, Figure  5B) . However, the suppression by DNQX of dl-PHPB-induced LTP improvement was far weaker than that of the NMDAspecific antagonist D-APV. These results suggest that dl-PHPB enhances LTP mainly through NMDA receptor modulation.
dl-PHPB restored the phosphorylation of GluN2B in the hippocampus of APP/PS1 Tg mice NMDARs are thought to be highly important in the mechanisms of learning and memory. In this study, to further explore the possible mechanisms of the behavioral and LTP improvements upon dl-PHPB treatment, the protein expression levels of GluN1 and GluN2B in APP/PS1 Tg mice were measured by Western blotting. The mice and drug administration protocols used for this experiment were the same as those in the behavioral and LTP experiments.
As shown in Figure 6 , GluN1 and p-GluN2B levels in APP/ PS1 Tg mice were reduced to 72.2% and 59.1%, respectively, of WT control mice in hippocampus (n=4, P<0.05 vs WT control), but there was no significant change in the cortex. Furthermore, oral dl-PHPB treatment significantly increased the p-GluN2B level in the hippocampus (Tg dl-PHPB: 126.9%±24.8% of WT control group, n=4; P<0.05 vs Tg control group, Figure 6C ). The GluN1 level showed no change after dl-PHPB treatment in either the hippocampus or the cortex of the rat brain.
Discussion
dl-PHPB, a novel drug candidate for treating cerebral ischemia, may be useful for the treatment of AD, based on our preliminary studies showing that dl-PHPB ameliorated behavioral deficits induced by cerebral hypoperfusion or Aβ icv infusion [2] . However, the effects of dl-PHPB on memory loss amelioration and the possible underlying mechanism remain to be investigated.
AD is a progressive neurological disorder. One of the most important aspects of its pathogenesis is the accumulation of Aβ peptide. Aβ, a peptide of 40 or 42 amino acids in length, is derived from the proteolytic processing of APP [22] . Many studies have used a mouse model overexpressing mutant human APP and PS1; this mouse exhibits age-dependent increases in the levels of Aβ peptides and develops robust amyloid plaque pathology like that in AD [23] . In the present study, to investigate the possibility of treating AD with dl-PHPB, the effects of dl-PHPB on LTP were investigated using 2 animal models: rats icv injected with Aβ 1-42 and APP/PS1 Tg mice.
It is well known that passive avoidance learning is based on hippocampus-related memory [24] . Notably, the Tg mice aged 
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Acta Pharmacologica Sinica npg 14 months spent significantly less time on the experimental platform and had higher error frequencies than their WT littermates, showing profound memory impairment. Long-term oral treatment with dl-PHPB increased the escape latency and decreased the error frequency in Tg mice. These results indicated that oral treatment with dl-PHPB ameliorated behavioral deficits in APP/PS1 Tg mice.
In the experiments shown in Figure 2 , dl-PHPB was applied intracerebroventricularly, whereas it was administered orally in the experiments shown in Figure 3 . The experimental conditions were different in these 2 sets of experiments, and both types of administration have advantages. As explained above, in this study, oral treatment with dl-PHPB rescued LTP and memory deficits in rats acutely injected with Aβ 1-42 and in APP/PS1 mice. It is thought that the results of oral administration may be similar to the clinical application of dl-PHPB. By contrast, icv injection allowed us to study the direct effects of drug action on targets in the brain. In our study, the LTP levels after oral treatment and icv injection in WT rats are not consistent. This discrepancy may be caused by the difference in pharmacokinetics and in the drug distribution of dl-PHPB in vivo. Our study showed that dl-PHPB promoted LTP when it was icv injected, indicating that dl-PHPB acted directly on the hippocampus. However, the mechanisms underlying this effect remain to be studied.
Increasingly, investigations are demonstrating that a deficit in synapses rather than in neurons might be the primary problem in the early phases of AD [25] . LTP, a form of synaptic plasticity, is widely used as the primary experimental method for exploring the synaptic basis of learning and memory in the brain [26] , particularly in the hippocampus, which is thought to play a major role in memory formation and consolidation processes. There is substantial evidence indicating that Aβ peptides or amyloid-derived diffusible ligands elicit neuronal [6, 27, 28] . In the current study, we show that long-term oral treatment with dl-PHPB may rescue the LTP inhibition induced by Aβ . The treatment dosage used was also therapeutically beneficial for improving behavior in our previous study. Our results indicated that dl-PHPB blocked Aβ 1-42 -induced synaptic dysfunction. However, the mechanisms of this process are not clear and possibly include changes in the NMDA receptors [29] , K + channel activity [30, 31] and voltagedependent calcium channel activity [32] [33] [34] . In addition, the function of the acetylcholine system is also important for LTP induction. Our previous studies have demonstrated that dl-PHPB had almost no effect on delayed rectifier and A-type K + channel currents, nor did it affect the function of the acetylcholine system (data not shown). Therefore, the present study focused on the effects of dl-PHPB on Aβ and on NMDAreceptor-related activity of LTP.
Increasingly, the impairment of synaptic plasticity with age has been observed in AD Tg mice compared to their WT littermates. Previous studies have indicated that synaptic plasticity is strongly impaired in APP/PS1 Tg mice as well as in other APP Tg mice [35] . Consistent with these results, we found that LTP was attenuated in 14-month-old APP/PS1 Tg mice. Oral treatment with dl-PHPB led to an increase in LTP in APP/PS1 Tg mice. In combination with the beneficial effects of dl-PHPB on synaptic dysfunction and behavioral deficits, these results indicated that dl-PHPB has a therapeutic effect in animal models with APP and PS1 mutations.
Increasingly, studies are indicating that modifications of excitatory amino-acid receptors, such as NMDA, AMPA and kainate receptors, are important mechanisms in the process of learning and memory. In particular, the NMDA receptors are important for activating LTP. Previous studies have shown that LTP induction by HFS in the hippocampal DG requires the activation of postsynaptic NMDA receptors [36, 37] . Consistent with these reports, the LTP we induced in this study was strongly inhibited by the NMDA antagonist D-APV. It was also inhibited by DNQX, an AMPA/kainate receptor antagonist, which is consistent with a previous report [38] . Although the IC 50 of DNQX for inhibiting AMPA/kainate receptors is in the 1-10 μmol/L range, the concentration reported for inhibiting LTP might be in the 10-50 μmol/L range [39] . In addition, previous studies have shown that DNQX (100-200 μmol/L) is insufficient to block the baseline of glutamate-evoked postsynaptic potentials [40] ; therefore, in our study, 100 μmol/L DNQX was chosen to fully inhibit LTP with no obvious effects on basal synaptic transmission. We also found that the protein expression levels of the NMDA receptors GluN1 and p-GluN2B were decreased in the hippocampus of APP/PS1 Tg mice. Long-term oral treatment with dl-PHPB significantly restored the p-GluN2B level in APP/PS1 Tg mice, but it did not affect the GluN1 level. Our results indicated that NMDA receptors, especially GluN2B, played an important role in the beneficial effects of dl-PHPB on LTP deficits. Interestingly, some previous studies [41, 42] have shown that overexpression of GluN2B in the forebrains of Tg mice leads to enhanced activation of NMDA receptors, facilitating synaptic potentiation. These mice exhibited superior ability in learning and memory in various behavioral tasks. Some groups have also shown that the phosphorylation level of GluN2B is lower in AD Tg mice than in their WT littermates [43] . In summary, our results suggest that the GluN2B receptor might be the target of dl-PHPB that drives the observed effects on LTP and memory loss amelioration.
Previous experiments have suggested that LTP involves the NR2A receptors [44, 45] and that long-term depression is dependent on the NR2B receptors [46] . Some groups have also shown that the phosphorylation level of NR2B is lower in AD Tg mice than in WT littermates. For example, papers from Tang YP's group have shown that Tg mice overexpressing NR2B exhibit superior ability in learning and memory in various behavioral tasks [41] . These studies demonstrate that NR2B is the predominant tyrosine-phosphorylated protein in the PSD and that Tyr 1472 is the major phosphorylation site. The phosphorylation of NR2B at Tyr 1472 is thought to stabilize NMDA receptors on the cell surface and make them functionally active. Therefore, we tested NR2B expression and phosphorylation as an important factor reflecting the process of learning and memory. NR2B expression was relatively high in the Tg control group. The reasons for this phenomenon are unclear. The most likely explanation is that in adult APP/PS1 mice, synaptic excitation is abnormal, and receptor activities are imbalanced, which might in turn lead to neuronal impairment and deficits in LTP. However, the exact mechanisms remain to be further investigated.
NR1 is an essential NMDA receptor subunit and is expressed throughout the brain. NR1 subunits bind the coagonist glycine, which is critical for activation of the NMDA receptors. In the current study, we assessed NR1 expression as a reflection of the total NMDA level, including the NR2A-and NR2B-NMDA receptors. Several phosphorylation sites on NR1 are required for increasing NMDA receptor surface expression. We will test the phosphorylation level of GluN1 in further studies.
In our previous studies, dl-PHPB was shown to ameliorate ischemic stroke by increasing cerebral blood flow, reducing infarct volume and improving neurobehavioral deficits in a rat model of tMCAO [1] . Recently, dl-PHPB was found to play a role in neuronal apoptosis through mediating the expression of genes involved in apoptosis [47] . All of these findings indicate that there may be multiple mechanisms involved in the effects of dl-PHPB, and these effects of dl-PHPB might support neuronal protection and the treatment of AD in a nonspecific manner, in addition to the effects on NMDA receptors.
In summary, we demonstrated for the first time that dl-PHPB ameliorated the learning and memory deficits and restored the impairment of LTP in AD Tg mice in vivo. Furthermore, the beneficial effects of dl-PHPB might occur through the various receptor subunits of NMDA, especially GluN2B, which is closely linked to learning and memory. Our results indicated that dl-PHPB might promote synaptic plasticity and improve cognition under pathological conditions. Therefore, dl-PHPB 
